Get the Stockscreener App
0.872
2.30%
0.0196
Valion Bio Inc stock is traded at $0.872, with a volume of 36,802.
It is up +2.30% in the last 24 hours and up +0.00% over the past month.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
See More
Previous Close:
$0.8524
Open:
$0.86
24h Volume:
36,802
Relative Volume:
0.55
Market Cap:
$2.79M
Revenue:
$482.00K
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.0935
EPS:
-9.327
Net Cash Flow:
$-6.63M
1W Performance:
+7.42%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.8305
$0.95
1-Week Range:
$0.80
$0.95
52-Week Range:
$0.80
$1.1996
Valion Bio Inc Stock (VBIO) Company Profile
Name
Valion Bio Inc
Sector
Industry
Phone
(888)276-6888
Address
1305 E. HOUSTON STREET, SAN ANTONIO
Compare VBIO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.00 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.40 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.50 | 432.93M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.29 | 288.61M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.54 | 0 | 0 | 0 | 0 | 0.00 |
Valion Bio Inc Stock (VBIO) Latest News
Valion Bio (VBIO) Stock Analysis Report | Financials & Insights - Benzinga
VBIO Stock Price, Quote & Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
VBIO Price Today: Valion Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VBIO Stock Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
Quest Diagnostics Declares Quarterly Cash Dividend - Weekly Voice
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME - Barchart.com
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work - MSN
Valion Bio Inc (VBIO-Q) Stock Price and News - The Globe and Mail
Valion Bio (VBIO) Reports Financial Position and Strategic Focus for 2026 - GuruFocus
Valion Bio's Velocity Bioworks Secures Exclusive Commercial Lice - GuruFocus
VBIO Technical Analysis & Stock Price Forecast - Intellectia AI
VBIO PE Ratio & Valuation, Is VBIO Overvalued - Intellectia AI
VBIO Should I Buy - Intellectia AI
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS - GuruFocus
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook - Intellectia AI
Valion Bio Reports Q1 Results, Advances Entolimod Platform - TipRanks
Valion Bio, Inc. Common Stock Q1 2026 Earnings Call Transcript - MarketBeat
Valion Bio subsidiary secures exclusive NMR platform license By Investing.com - Investing.com South Africa
Valion Bio, Inc. 1Q 2026: Revenue $24K, Net loss $(6.20M), EPS $(2.23) — 10-Q Summary - TradingView
Valion Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Valion Bio, Inc. Quarterly Earnings Report - Stock Titan
Valion Bio subsidiary secures exclusive NMR platform license - Investing.com
Transcript : Valion Bio, Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Valion Bio Q1 2026 Earnings Call: Complete Transcript - Benzinga
Valion Bio reports first quarter 2026 financial results - marketscreener.com
Valion Bio Reports First Quarter 2026 Financial Results - TradingView
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform - PR Newswire
Valion Bio Inc (VBIO) Earnings Calendar_Earnings Forecast_Financial Report and Earnings Call - Tiger Brokers
Valion Bio (VBIO.US) will release its earnings report after the market closes on May 14. - Moomoo
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 - Morningstar
3i group (TIVC) files amendment showing 9.99% holding and convertible exposure - Stock Titan
Number of shareholders of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
New San Antonio plant brings 45 jobs, backs radiation drug - Stock Titan
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™ - Barchart
Valion Bio Appoints Melinda Lackey as General Counsel - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Valion Bio Names Melinda Lackey General Counsel as It Advances Immunotherapy Pipeline and Regulatory Strategy - citybiz
VBIO News | VALION BIO INC (NASDAQ:VBIO) - ChartMill
Valion Bio receives protocol for radiation syndrome drug study - Investing.com
Valion Bio receives protocol for radiation syndrome drug study By Investing.com - Investing.com Australia
Valion Bio receives first FDA-precedent study protocol from NIAID for Entolimod; federal agency to fully fund BLA-enabling in vivo program and co-navigate FDA submission - marketscreener.com
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION - PR Newswire
Valion Bio Taps Legal-Science Hybrid to Drive Growth Strategy - BriefGlance
Valion Bio (VBIO) grants 45,000 stock options to general counsel - Stock Titan
Valion Bio (VBIO) General Counsel Melinda Lackey becomes reporting insider with Form 3 - Stock Titan
Valion Bio (Nasdaq: VBIO) hires Melinda Lackey as General Counsel - Stock Titan
Valion Bio Inc Stock (VBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Valion Bio Inc Stock (VBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Valauri Christina Rizopoulos | Director |
Apr 01 '26 |
Buy |
0.95 |
19,000 |
18,008 |
19,000 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):